Pure Global
NCT05760144

Endometrial Biopsy in Progestin Contraceptive Users

Oregon Health and Science University·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Contraception
Drug/Device/Intervention
DMPA
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Oregon Health and Science University
Location
Portland, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2023
End date
Nov 01, 2025
Enrollment
52 participants
Primary outcome

The proportion of participants who experienced endometrial changes

Summary

The purpose of the study is to learn more about menstrual changes in progestin contraception
 users. The investigators are hoping to find out what changes in the endometrium lead to
 different bleeding patterns during the first year of progestin contraception use.
 Participants will choose to receive the contraceptive implant (Etonogestrel implant also
 called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA)
 also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial
 biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy
 tests. Participants will also use a daily text message or email diary to report bleeding
 patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the
 entire endometrium using single-cell RNA seq data (sCRNAseq).

ICD-10 classifications
Contraceptive managementOral contraceptivesOther contraceptive managementGeneral counselling and advice on contraceptionPersonal history of contraception
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05760144
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05760144 through Pure Global AI's free database. This Phase 1 trial is sponsored by Oregon Health and Science University and is currently Recruiting. The study focuses on Contraception. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.